Finanzen von IGM Biosciences Inc (IGMS)IGMSIGM Biosciences Inc

Evaluating the bottom line, IGM Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 90.72%, while the net margin is 67.94%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IGMS converts its operational activities into shareholder value.

In the context of the broader market, IGMS competes directly with industry leaders such as ASRT and ADAG. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, IGMS's gross margin of 100.00% stands against ASRT's 14.28% and ADAG's 100.00%. Such benchmarking helps identify whether IGM Biosciences Inc is trading at a premium or discount relative to its financial performance.